HIF1A and chronic kidney disease: Pharmacologic inhibition of HIF-1 with YC-1 compound [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] abrogated these effects and slowed the development of fibrosis in mice subjected to UUO [15], suggesting that HIF-1 may represent a novel pharmacologic target to slow the progression of CKD.